New Treatments & Clinical Trials for Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia is a blood cancer that moves fast, producing too many immature white blood cells that crowd out healthy ones. It's the most common childhood cancer, but also affects adults. Treatment typically starts with chemotherapy, followed by stem cell transplant in many cases. Cure rates in children now exceed 90%, while adult outcomes have improved but remain lower.

What's actually going on in research

Trials are testing CAR T-cell therapy, which reprograms immune cells to hunt leukemia, and bispecific antibodies that bridge cancer cells to killer T cells. Blinatumomab and inotuzumab ozogamicin have already changed treatment for relapsed disease. Researchers are also studying ways to reduce chemotherapy toxicity in children, improve adult outcomes with targeted drugs like tyrosine kinase inhibitors for Ph-positive ALL, and prevent relapse after transplant.

What to know before you search

Eligibility typically depends on ALL subtype (B-cell or T-cell), genetic markers like Philadelphia chromosome, prior treatments, and disease status (newly diagnosed, relapsed, or refractory).

What types of trials are currently open

• Frontline treatment trials — Testing new drug combinations or CAR T-cell therapy as initial treatment, aiming to cure more patients without relapse.
• Relapsed/refractory trials — For leukemia that returns or doesn't respond to standard treatment. These often test CAR T, bispecific antibodies, or novel targeted drugs.
• Transplant trials — Testing ways to improve stem cell transplant outcomes, reduce complications like graft-versus-host disease, or prevent relapse after transplant.
• Survivorship trials — Studies focused on reducing long-term side effects of chemotherapy and radiation, especially heart and brain problems in childhood survivors.
• Supportive care trials — Testing drugs or strategies to manage infections, nausea, pain, and other treatment side effects.